Medidata Solutions (NASDAQ:MDSO)

CAPS Rating: 3 out of 5

Results 1 - 7 of 7

Recs

0
Member Avatar km00nster (< 20) Submitted: 6/20/2014 11:14:21 AM : Outperform Start Price: $42.41 MDSO Score: +4.48

As more healthcare providers are moving to the cloud, MDSO will definately benefit. People really underestimate the potential of the cloud.

Recs

0
Member Avatar TMFTypeoh (82.50) Submitted: 10/24/2013 3:58:00 PM : Outperform Start Price: $61.08 MDSO Score: -41.32

Riding to cloud wave

Recs

0
Member Avatar NiksurfsInvestmt (26.14) Submitted: 8/6/2013 7:36:31 PM : Outperform Start Price: $43.24 MDSO Score: -13.55

Actually got in today at a lower price than is stated on my "entry price".

Efficiency is one of the key components in the game for producing monumental ROI, if executed well. Few catalysts can rival the cost efficiencies of a well done SaaS model.

MDSO has a laser focus and well articulated vision for being the best in class information supplier for Clinical Development Solutions within the life sciences vertical. This is an area rife with cost overruns and a penchant for in-efficiency. Time to market is a huge item that impacts profitability for all Biotech & Pharma companies. It stands to be even more critical in the Genomics category.

MDSO has a customer retention rate and a demonstrated ability to capture new clients at an unprecedented rate. Matching this with a building SaaS business model and a growing silo of industry specific data and process models, I am glad to be joining them on this ride.

It is still early and with a light enough float along with new capital coming on line, yes despite the dilution forthcoming, this for my money, is a buy and hold candidate. I do wish I would have found it earlier but I very content with starting my new position with them as of today.

Recs

0
Member Avatar DanaFBlankenhorn (< 20) Submitted: 2/28/2013 1:24:29 PM : Outperform Start Price: $25.98 MDSO Score: +44.82

They have succeeded in taking control of the clinical trials market, but this market is not subject to the stimulus the way the EHR market is.

Recs

0
Member Avatar rjs157 (58.96) Submitted: 10/10/2012 9:56:29 PM : Outperform Start Price: $19.94 MDSO Score: +91.41

SaaS cloud storage of medical records...genius

Recs

0
Member Avatar jalibistje (< 20) Submitted: 12/25/2009 2:16:53 PM : Outperform Start Price: $7.70 MDSO Score: +424.61

I think that Elan's Tysabri is becomming the best for all MS patients and only for this the stock can outperform the market. Elan also has several issues for the disease of Alsheimer and that can take the stock going like GILD did the past ten year.

Recs

0
Member Avatar kong777 (78.36) Submitted: 9/29/2009 2:01:42 PM : Outperform Start Price: $7.74 MDSO Score: +409.72

The bottom for this company is thin . But the beauty inside is impressive . Robust revenue growth year by year . The cash flow is strong. Net income might be low but it is norm when your company is in growing mode. A lot of depreciation makes the bottom line look bad but CF is far more better.

The revenue stream is recurring because it is in service business. 80% of customer retention . And the Biotech sector is blooming like Obama said and the aging economy . Everything looks great for this small company. So I would say "long term buy"

Results 1 - 7 of 7

Featured Broker Partners


Advertisement